PUBLISHER: Global Market Insights Inc. | PRODUCT CODE: 1568404
PUBLISHER: Global Market Insights Inc. | PRODUCT CODE: 1568404
Narcolepsy Therapeutics Market, Opportunity, Growth Drivers, Industry Trend Analysis and Forecast, 2024-2032
The Global Narcolepsy Therapeutics Market size is expected to record an 8.2% CAGR between 2024 and 2032, led by ongoing R and D, heightened awareness, and enhanced diagnostic practices.
Of late, researchers are delving into novel treatments while fine-tuning existing ones, aiming to better manage narcolepsy symptoms and uplift the quality of life of patients. Concurrently, heightened awareness and superior diagnostic methods are ensuring timely and precise diagnoses, leading to increased treatment uptake. For instance, in May 2023, Zevra Therapeutics celebrated a milestone with the U.S. FDA's acceptance of its IND application for KP1077, underscoring a leap forward in narcolepsy therapeutics.
The industry is segmented based on disease type, treatment type, distribution channel, and region.
Narcolepsy therapeutics market share from the tricyclic antidepressants treatment type segment is expected to witness substantial growth through 2032, due to their proven efficacy in symptom management. Prescribed to combat excessive daytime sleepiness and enhance sleep quality, tricyclic antidepressants work by modulating brain neurotransmitters, stabilizing sleep patterns, and alleviating narcolepsy symptoms. Moreover, ongoing research is fine-tuning dosage recommendations and investigating effects across various subtypes of narcolepsy.
In terms of distribution channel, the narcolepsy therapeutics market from the hospital pharmacies segment is slated to generate notable revenue during 2024-2032, on account of rising adoption for providing specialized medications and personalized treatment plans. Hospital pharmacies work closely with healthcare providers to ensure that patients receive appropriate narcolepsy medications, such as stimulants and antinarcoleptic drugs. They are also involved in monitoring medication adherence and managing potential side effects to optimize treatment outcomes.
Europe narcolepsy therapeutics industry size is likely to record a notable CAGR through 2032 fueled by bolstered government and regulatory backing. Policymaking and funding initiatives are being rolled out to propel narcolepsy research and treatment development. Enhanced regulatory frameworks, coupled with financial R and D incentives, are streamlining access to treatments to ensure swift and efficient delivery of new therapies to patients across the region.
Table of Contents
Chapter 1 Methodology and Scope
- 1.1 Market scope and definitions
- 1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
- 1.3 Base estimates and calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
- 1.4 Forecast model
- 1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources
Chapter 2 Executive Summary
- 2.1 Industry 360° synopsis
Chapter 3 Industry Insights
- 3.1 Industry ecosystem analysis
- 3.2 Industry impact forces
- 3.2.1 Growth drivers
- 3.2.1.1 Increasing prevalence of narcolepsy
- 3.2.1.2 Introduction of novel therapeutic products, and advancements in R and D
- 3.2.1.3 Growing awareness and diagnosis
- 3.2.2 Industry pitfalls and challenges
- 3.2.2.1 Adverse effects and risks related to narcolepsy drugs
- 3.2.2.2 Delayed diagnosis or misdiagnosis
- 3.2.1 Growth drivers
- 3.3 Growth potential analysis
- 3.4 Regulatory landscape
- 3.5 Reimbursement scenario
- 3.6 Porter's analysis
- 3.7 PESTEL analysis
- 3.8 Future market trends
- 3.9 Gap analysis
- 3.10 Pipeline analysis
Chapter 4 Competitive Landscape, 2023
- 4.1 Introduction
- 4.2 Company matrix analysis
- 4.3 Competitive analysis of major market player
- 4.4 Competitive positioning matrix
- 4.5 Strategy dashboard
Chapter 5 Market Estimates and Forecast, By Disease Type, 2021 - 2032 ($ Mn)
- 5.1 Key trends
- 5.2 Narcolepsy with cataplexy (type 1)
- 5.3 Narcolepsy without cataplexy (type 2)
- 5.4 Secondary narcolepsy
Chapter 6 Market Estimates and Forecast, By Treatment Type, 2021 - 2032 ($ Mn)
- 6.1 Key trends
- 6.2 Central nervous system stimulants
- 6.3 Sodium oxybate
- 6.4 Selective serotonin reuptake inhibitor
- 6.5 Tricyclic antidepressants
- 6.6 Histamine H3 receptor antagonists
Chapter 7 Market Estimates and Forecast, By Distribution Channel, 2021 - 2032 ($ Mn)
- 7.1 Key trends
- 7.2 Retail pharmacies
- 7.3 Hospital pharmacies
- 7.4 Other pharmacies
Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)
- 8.1 Key trends
- 8.2 North America
- 8.2.1 U.S.
- 8.2.2 Canada
- 8.3 Europe
- 8.3.1 Germany
- 8.3.2 UK
- 8.3.3 France
- 8.3.4 Italy
- 8.3.5 Spain
- 8.3.6 Netherlands
- 8.3.7 Rest of Europe
- 8.4 Asia Pacific
- 8.4.1 China
- 8.4.2 Japan
- 8.4.3 India
- 8.4.4 Australia
- 8.4.5 South Korea
- 8.4.6 Rest of Asia Pacific
- 8.5 Latin America
- 8.5.1 Brazil
- 8.5.2 Mexico
- 8.5.3 Argentina
- 8.5.4 Rest of Latin America
- 8.6 Middle East and Africa
- 8.6.1 Saudi Arabia
- 8.6.2 South Africa
- 8.6.3 UAE
- 8.6.4 Rest of Middle East and Africa
Chapter 9 Company Profiles
- 9.1 Avadel Pharmaceuticals
- 9.2 Axsome Therapeutics Inc.
- 9.3 Harmony Biosciences
- 9.4 Jazz Pharmaceuticals PLC
- 9.5 Mylan N.V.
- 9.6 Novartis AG
- 9.7 Rhodes Pharmaceuticals L.P.
- 9.8 Shionogi Inc.
- 9.9 Takeda Pharmaceutical Company
- 9.10 Teva Pharmaceuticals Industries Ltd
- 9.11 XWPharma Ltd.
